Sign in
Explore the registryTrack Lebrikizumab's trials

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

LebrikizumabCompletedCompletedPhase 3Open NCT04146363 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…

NCT04146363 · Trial Tracker · ComplyRx